Pazamet

**Pazamet** is a chewable tablet formulation of **metformin hydrochloride**, developed by Boston Therapeutics as an alternative delivery format for the standard-of-care treatment of type 2 diabetes. Metformin acts by increasing the sensitivity of liver, muscle, and fat tissues to insulin, thereby lowering blood glucose levels. The company received FDA approval in 2012 to file an Abbreviated New Drug Application (ANDA) for this formulation, with no additional clinical studies required for safety and efficacy, referencing Bristol-Myers Squibb's Glucophage as the listed drug; it incorporates optimized complex carbohydrate chemistry (mannans) for improved palatability and absorption.[4][7][11]

Brand names

Pazamet